<DOC>
	<DOCNO>NCT02047773</DOCNO>
	<brief_summary>From British Thoracic Guidelines1 PUBMED search randomise control trial explore optimum antibiotic duration chest infection . The standard course intravenous antibiotic exacerbation bronchiectasis 14 day . This preliminary open label study ass whether feasible stop treatment earlier ( day 8 day 11 ) bacterial load low absent day 7 day 10 ( take 24 hour result process ) . All patient therefore minimum 7 day intravenous antibiotic . The intravenous antibiotic chosen routinely use exacerbation bronchiectasis . Our hypothesis patient could personalise treatment able stop antibiotic sputum bacterial load low ( &lt; 10^6 colony form units/ml ( cfu/ml ) ) .</brief_summary>
	<brief_title>Bacterial Load Guided Therapy Severe Bronchiectasis Exacerbations</brief_title>
	<detailed_description>We investigate 90 patient bronchiectasis develop exacerbation define British Thoracic Society guideline require intravenous antibiotic . After consent , patient randomly allocate one two arm ( computer generate ) . 45 patient length treatment guide bacterial load 45 patient 14 day IV Meropenem . Next attend baseline visit . Here , ask provide 24 hour sputum collect day prior visit , spontaneous sample collect within 4 hour rise ( sample use sputum colour microbiological analysis ) , undergo spirometry testing , incremental shuttle walk test , blood sampling ( inflammatory marker Erythrocyte Sedimentation Rate , C Reactive Protein , Full Blood Count , procalcitonin ) , fill leicester cough questionnaire ass cough ( LCQ ) health relate quality life questionnaire ( St George 's respiratory questionnaire , SGRQ ) . All patient start intravenous meropenem 2g , tds ( assume previous document resistant microbiology result allergy ) . They return day 7 check clinical progress . At time provide 24hour sputum , spontaneous sputum sample blood sample document . Arm one ( intervention arm ) antibiotic stop day 8 bacterial load less 10^6cfu/ml . Arm two continue intravenous meropenem regardless bacterial count . All patient return day 10 , provide 24hour sputum , spontaneous sputum sample blood sample document . Arm one ( intervention arm ) antibiotic stop day 11 bacterial load less 10^6cfu/ml . Arm two continue intravenous meropenem regardless bacterial count . All patient return day 14 . All assessment baseline repeat except LCQ SGRQ . All antibiotic patient stop 14 day treatment . All patient return day 21 assessment repeat . The LCQ SGRQ complete day 21 . The date time next exacerbation record next routine outpatient appointment .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Patients age 18 An establish primary diagnosis non cystic fibrosis bronchiectasis Patients need meet criterion need intravenous antibiotic therapy . Only first exacerbation per patient use . Patients organisms resistant vitro Meropenem ( know previous sputum microbiology rare cohort ) ; Current smoker exsmokers less 1 year ; Cystic fibrosis ; Active allergic bronchopulmonary aspergillosis ; Active tuberculosis ; Poorly control asthma necessitate long term oral corticosteroid ; Pregnancy breast feeding ; Active malignancy ; Severe chronic obstructive pulmonary disease ( COPD ) long term oxygen therapy ; Patients require non invasive invasive ventilation ; Known allergy Meropenem rare cohort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>bronchiectasis</keyword>
	<keyword>intravenous antibiotic</keyword>
	<keyword>duration antibiotic course</keyword>
	<keyword>side effect</keyword>
	<keyword>bacterial load</keyword>
</DOC>